ePrints

Safety and tolerability of one-year intramuscular testosterone regime to induce puberty in older men with CHH

Lookup NU author(s): Dr Agnieszka Pazderska, Dr Stephen Ball, Professor Timothy Cheetham, Dr Richard Quinton

Downloads

• Published version [.pdf]

Licence

This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License (CC BY-NC 4.0).

Abstract

© 2018 The authors Published by Bioscientifica Ltd. We present herein our 20-year experience of pubertal induction in apubertal older (median age 56 years; range 38.4–69.5) men with congenital hypogonadotrophic hypogonadism (n = 7) using a simple fixed-dose and fixed-interval intramuscular testosterone that we originally pioneered in relation to achieving virilisation of natal female transgender men. This regime was effective and well tolerated, resulting in complete virilisation by around 1 year after treatment initiation. No physical or psychological adverse effects were encountered in this group of potentially vulnerable individuals. There were no abnormal excursions of laboratory parameters and extended follow-up beyond the first year of treatment revealed remarkable improvements in bone density. We highlight advantages to both patients and physicians of this regime in testosterone-naïve older men with congenital hypogonadism and discourage the over-rigid application to such patients of treatment algorithms derived from paediatric practice in relation to the evaluation and management in younger teenagers with delayed puberty of uncertain cause.

Publication metadata

Author(s): Pazderska A, Mamoojee Y, Artham S, Miller M, Ball SG, Cheetham T, Quinton R

Publication type: Article

Publication status: Published

Journal: Endocrine Connections

Year: 2018

Volume: 7

Issue: 1

Pages: 133-138

Print publication date: 01/01/2018

Acceptance date: 27/11/2017

Date deposited: 22/01/2018

ISSN (electronic): 2049-3614

Publisher: BioScientifica Ltd

URL: https://doi.org/10.1530/EC-17-0241

DOI: 10.1530/EC-17-0241

Altmetrics

Share